Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-iii symbols : Azn save search
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
Published: 2024-02-23 (Crawled : 21:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 1.29%
H: 1.49%
C: 1.34%
show
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
Published: 2023-12-18 (Crawled : 00:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 1.03%
H: 1.08%
C: 0.73%
breast cancer trials plus initiated
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
Published: 2023-12-11 (Crawled : 08:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.46%
H: 0.22%
C: -0.06%
ultomiris trial
Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Published: 2023-10-23 (Crawled : 19:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -1.57%
H: 1.06%
C: 0.36%
breast her2 cancer trial negative
Datopotamab Deruxtecan Improved Progression-Free Survival Versus Chemotherapy in Patients with Previously Treated Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Published: 2023-10-23 (Crawled : 19:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -1.57%
H: 1.06%
C: 0.36%
lung cancer cell trial
TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial
Published: 2023-09-11 (Crawled : 19:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -3.31%
H: 1.02%
C: 0.97%
tagrisso lung cancer trial plus
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients with Advanced Non Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Published: 2023-07-03 (Crawled : 08:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -6.26%
H: 0.33%
C: -2.74%
lung cancer cell trial
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
Published: 2022-12-07 (Crawled : 15:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.45%
H: 0.64%
C: -0.03%
enhertu risk breast positive cancer her2- her2 metastatic breast cancer
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
Published: 2022-08-15 (Crawled : 09:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.92%
H: 0.22%
C: -0.65%
enhertu treatment disease trial positive cancer her2- her2 metastatic breast cancer
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
Published: 2022-08-01 (Crawled : 10:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: -14.87%
H: 4.09%
C: 4.09%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -3.9%
H: 0.0%
C: 0.0%
NVO | $123.01 0.21% 2.6M
|
Health Technology
|
| O: -0.21%
H: 0.41%
C: -0.73%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
IPHA | $2.35 3.6K
|
Health Technology
|
| O: -11.25%
H: 0.0%
C: -1.06%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.44%
H: 0.53%
C: -1.31%
pharma update study
TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer
Published: 2022-06-13 (Crawled : 13:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -1.4%
H: 0.4%
C: -0.7%
trial cancer negative initiated breast cancer phase 3
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
Published: 2022-05-27 (Crawled : 14:20) - biospace.com/
AZNCF | $138.24 800
|
Health Technology
|
| O: -2.27%
H: 2.43%
C: -0.25%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.15%
H: 0.9%
C: 0.9%
lupus trial
Evusheld long-acting antibody combination retains neutralising activity against Omicron variants BA.4 and BA.5, according to new study from University of Oxford
Published: 2022-05-25 (Crawled : 17:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -0.45%
H: 0.89%
C: 0.54%
antibody
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
Published: 2022-04-29 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
NVO | $123.01 0.21% 2.6M
|
Health Technology
|
| O: 5.98%
H: 1.44%
C: -0.42%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
IPHA | $2.35 3.6K
|
Health Technology
|
| O: 11.11%
H: 3.67%
C: -4.33%
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.53%
H: 2.37%
C: 0.26%
trial payment cancer phase 3
ENHERTU® Additional Analyses Further Reinforce Groundbreaking Efficacy in Patients with HER2 Positive Metastatic Breast Cancer
Published: 2021-12-09 (Crawled : 19:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: 0.27%
H: 0.63%
C: -0.58%
enhertu positive cancer breast cancer her2- her2 metastatic breast cancer
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Published: 2021-11-18 (Crawled : 21:00) - biospace.com/
AZN | $68.3 -0.09% 2M
|
Health Technology
|
| O: -1.46%
H: 0.33%
C: -0.32%
positive cancer phase 3 breast cancer trial initiated hormone her2+ her2- her2 metastatic breast cancer
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.